Claritev Corporation (CTEV) shares are soaring 5.95% in pre-market trading on Wednesday following the release of its second-quarter 2025 financial results. The technology, data, and insights company reported better-than-expected performance and provided an improved outlook for the full year, sparking investor optimism.

The company's Q2 2025 results showed notable improvements across key financial metrics. Claritev reported revenues of $241.6 million, marking a 3.5% increase compared to the same period last year. More significantly, the company dramatically reduced its net loss to $62.6 million, a substantial improvement from the $576.7 million loss recorded in Q2 2024. This considerable reduction in losses appears to be a primary driver behind the stock's pre-market surge.

Adding to the positive sentiment, Claritev updated its 2025 guidance, projecting revenues to be flat to a 2% increase from the previous year. The company also revised its free cash flow guidance from a negative range of $(75) million to $(65) million to a more optimistic range of $(20) million to $20 million. This improved outlook, coupled with the company's focus on making healthcare more affordable and transparent, seems to have resonated well with investors, contributing to the stock's significant pre-market gain.